A great summary of the emerging light at the end of the tunnel. Young biopharma startups may have more optimism. At the end of the day, the Crisis may have brought some fiscal and portfolio discipline, which is positive. Leaner, more outsourced Pharma also has a significant trickle down opportunity for young companies. In particular, the emerging trend in companion diagnostics.
http://lnkd.in/t4uQ-a
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022